Malignant Mesothelioma - Epidemiology and Market Forecast-2028

Albany, NY -- (SBWire) -- 04/24/2019 --Malignant Mesothelioma - Epidemiology and Market Forecast-2028

An average of 1.05 mesothelioma cases per 100,000 persons was diagnosed annually in the United States.

1. Men represent a majority of new cases, the gender gap is steadily closing with women now accounting for nearly one-fourth of all cases.
2. Mesothelioma is not among the 20 most common cancers in the United Kingdom accounting for less than 1% of all new cancer cases.
3. Out of 929 cases of mesothelioma, the majority was affected by the pleura, followed by peritoneum, pericardium, and tunica vaginalis testis

DelveInsight launched a new report on Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

1. Malignant Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Mesothelioma epidemiology and Malignant Mesothelioma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Malignant Mesothelioma market report provides insights on the current and emerging therapies.
3. Malignant Mesothelioma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Malignant Mesothelioma market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Malignant Mesothelioma market.

"Based on the age-group distribution, majority of the cases were reported between 70 to 80 years."

Different types of treatments are available for patients with malignant mesothelioma. Some treatments are standard, and some are being tested in clinical trials. Mesothelioma can be hard to treat because it typically does not grow as a single tumour mass. It tends to spread along nearby surfaces, nerves, and blood vessels. This often makes it very hard to get rid of cancer completely with surgery and/or radiation. For some people, palliative procedures might be used to help treat some symptoms of mesothelioma.

Malignant Mesothelioma treatment typically employs a combination of two (or more) chemotherapy drugs.
Currently, pemetrexed (Alimta), which is approved by the US FDA and cisplatin is the most common combination used for malignant mesothelioma treatment. For malignant mesothelioma that cannot be operated on, an immunotherapy drug that prevents the creation of new blood vessels bevacizumab (Avastin) is often administered at the same time as the other two drugs.

Targeted therapies offer the impending advantages of disease-specific treatment with lesser side effects, however, sufficient activity has not yet been proven. Researchers continue to experiment with new drugs and new combinations of chemotherapy medications in hopes that they can find the best available to treat the disease and its symptoms. Malignant Mesothelioma market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2019-2028.

Key pharmaceutical players, worldwide, are working on the development of a drug for the mesothelioma treatment, and their products are thus expected to create a significant impact on the mesothelioma market size of therapeutic regimen.

The key players are:
1. Bristol-Myers Squibb
2. Ono Pharmaceutical
3. Polaris Group
4. Merck Sharp &Dohme
5. Epizyme
6. Boehringer Ingelheim
7. Novocure
8. Inhibrx
9. Targovax
10. Aldeyra Therapeutics
11. Deciphera Pharmaceuticals
And many others

Drugs covered

1. ADI-PEG 20
2. Pemetrexed combined with cisplatin or carboplatin
3. Tazemetostat
4. ONCOS-102
5. Rebastinib
6. ADX-1612
And many others

Table of contents

1. Report Introduction
2. Malignant Mesothelioma Market Overview at a Glance
3. Malignant Mesothelioma Disease Background and Overview
4. Malignant Mesothelioma Epidemiology and Patient Population
5. Malignant Mesothelioma Epidemiology of Mesothelioma by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 - Epidemiology (2017-2028)
5.3. Germany-Epidemiology (2017-2028)
5.4. France-Epidemiology (2017-2028)
5.5. Italy-Epidemiology (2017-2028)
5.6. Spain-Epidemiology (2017-2028)
5.7. United Kingdom-Epidemiology (2017-2028)
5.8. Japan-Epidemiology (2017-2028)
6. Malignant Mesothelioma Treatments & Medical Practices
7. Malignant Mesothelioma Marketed Products
8. Emerging Therapies
8.1. Key Cross Competition
8.2. ADI-PEG 20: Polaris Group
8.3. Tazemetostat: Epizyme
8.4. Pemetrexed combined with cisplatin or carboplatin: Novocure
9. Mesothelioma Market Size
10. Malignant Mesothelioma 7MM Country-Wise Market Analysis
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. Italy Market Size
10.5. Spain Market Size
10.6. United Kingdom Market Size
10.7. Japan Market Size
11. Market Drivers
12. Market Barriers
13. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight